TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

TG Therapeutics announced that CEO Michael S. Weiss will present at the H.C. Wainwright Global Investment Conference next week. The presentation will be available for on-demand viewing from May 24, 2022, at 7:00 AM ET through May 26, 2022. The webcast can be accessed on both the conference and TG Therapeutics website. The company focuses on innovative therapies for B-cell diseases, with a notable investigational drug, ublituximab, for treating relapsing forms of multiple sclerosis.

Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET

NEW YORK, May 20, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference taking place next week. A webcast of the presentation will be available for on demand download beginning on Tuesday, May 24, 2022, at 7:00 AM ET through Thursday May 26, 2022, on the conference website.

The webcast will also be available on TG’s website at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS). For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.

UKONIQ^® is a registered trademark of TG Therapeutics, Inc.

CONTACT:

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6

FAQ

When will TG Therapeutics' presentation at the H.C. Wainwright Global Investment Conference be available for download?

The presentation will be available for on-demand download starting May 24, 2022, at 7:00 AM ET.

What is the focus of TG Therapeutics?

TG Therapeutics focuses on developing and commercializing novel treatments for B-cell diseases.

What is ublituximab?

Ublituximab is an investigational glycoengineered monoclonal antibody developed by TG Therapeutics to treat patients with relapsing forms of multiple sclerosis.

Where can I watch the TG Therapeutics presentation?

You can watch the presentation on the H.C. Wainwright conference website and TG Therapeutics' official website.

Who is presenting for TG Therapeutics at the conference?

Michael S. Weiss, the Chairman and CEO of TG Therapeutics, will be presenting at the conference.